PCN18 ECONOMIC EVALUATION OF SUNITINIB VS. IMATINIB IN SECOND LINE FOR GASTROINTESTINAL TUMOR (GIST) IN BRAZIL

Authors :: C Hashizume
N Teich
W Follador
Source :: Value in Health. (7):A496
Publisher :: International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

Subjects :: Oncology
medicine.medical_specialty
Gastrointestinal tumors
GiST
business.industry
Sunitinib
Health Policy
Public Health, Environmental and Occupational Health
Imatinib
Second line
Internal medicine
Economic evaluation
medicine
business
medicine.drug

Full Text Access

Tools